(Q35873708)

10 August 2017

1 reference

title

Considerations with the use of biological therapy in the treatment of rheumatoid arthritis (English)

1 reference

10 August 2017

1 reference

Roy M Fleischmann

1

1 reference

10 August 2017

Imran Iqbal

series ordinal

2

1 reference

10 August 2017

Richard L Stern

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Drug Safety

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

391-403

1 reference

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Immunology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Tumor necrosis factor identified in multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

A lupus-like syndrome associated with infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Incidence of Cancer Among Patients With Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.391

21 January 2018

Identifiers

DOI

10.1517/14740338.3.5.391

1 reference

10 August 2017

1 reference